Achieve Life Sciences, Inc. (ACHV) company profile
Close on Nov 6, 2026Market cap $691.50MP/E –Yield –
About Achieve Life Sciences
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Achieve Life Sciences, Inc. is a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of cytisinicline. Its efforts center on addressing nicotine dependence by targeting adult combustible cigarette smoking and e-cigarette usage. Cytisinicline constitutes the organization's sole product candidate, developed to aid individuals seeking treatment for tobacco and nicotine addiction across the broader smoking cessation landscape.
The company operates across North America and Europe, maintaining facilities and operations in the United States, Canada, and the United Kingdom. Its principal executive offices are located in Bothell, Washington, alongside an executive office facility in Vancouver, British Columbia. Achieve relies on international plant sources grown outside the United States to secure necessary quantities of cytisinicline for its development activities.
Summary of the business section of Achieve Life Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Achieve Life Sciences, Inc.
- Founded
- 2015
- Headquarters
- Seattle, WA
- Address
- 22722 29th Dr. Se, Suite 100 98021
- Phone
- (425) 686-1500
- Website
- achievelifesciences.com
- Employees
- 28, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Vancouver, Canada
Stock & identifiers
- Ticker
- ACHV
- Other tickers
- QUIT
- Former tickers
- OGXI until Nov 9, 2017
- Exchange
- Nasdaq
- IPO date
- Oct 12, 1995
- Shares outstanding
- 103M, Aug 11, 2026
- Public float
- $103.96M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Jul 31, 2020; 1-for-10 reverse, May 24, 2018; 1-for-1410 reverse, Nov 9, 2017; 1-for-11 reverse, Aug 3, 2017; 1-for-18 reverse, Aug 21, 2008
- SEC CIK
- 949858
- CUSIP
- 004468500
- ISIN
- US0044685008
- FIGI
- BBG000FB8S62
- Share class FIGI
- BBG001S8JF14
- LEI
- 549300V82ZKZDTAU0A46
- EIN
- 95-4343413
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Andrew D. Goldberg | CEO and President, Director | 0 |
| Benjamin Halladay | Chief Financial Officer | – |
| Jerry Wan | Principal Accounting Officer | 46,764 |
| Mark K. Oki | Chief Financial Officer | 127,940 |
| Jaime Xinos | Chief Commercial Officer | 95,286 |
| Craig Donnelly | Chief Operations Officer | 52,372 |
| Mark Lawrence Rubinstein | Chief Medical Officer | 39,600 |
| Erik Atkisson | Chief Legal Officer | 0 |
| Cindy Jacobs | President & CMO | 143,214 |
| Richard Alistair Stewart | Director | 209,490 |
| Reid Alexander Waldman | Director | 0 |
| Christopher Nathan Martin | Director | 0 |
| Thomas Sellig | Director | 0 |
| Jeffrey S. Farrow | Director | 0 |
| Nancy R. Phelan | Director | 0 |
| Aaron Royston | Director | 0 |
| Lucian Iancovici | Director | 0 |
| Thomas Braxton King | Director | 455,000 |
| Bridget A. Martell | Director | 0 |
| Kristen B. Slaoui | Director | 0 |
| Stuart Duty | Director | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.37M | $1.50M | $964.00K | $203 | – |
| FY2024 John Bencich | $2.52M | $2.20M | $1.15M | $144 | – |
| FY2024 Richard Stewart | $1.74M | $1.49M | $1.15M | $144 | – |
| FY2023 | $1.70M | $1.64M | $1.28M | $168 | – |
| FY2022 | $1.50M | $1.07M | $1.19M | $30 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Richard Stewart Former Chief Executive Officer | $615.00K | $522.90K | – | $230.63K | $1.37M | -21% |
| Erik Atkisson Chief Legal Officer (4) | $130.26K | $853.15K | – | – | $983.40K | – |
| Jaime Xinos Former Chief Commercial Officer | $450.00K | $311.00K | $48.60K | $135.00K | $944.60K | -11% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 28 employees, of whom 11 were engaged in research and development functions, including clinical development, regulatory affairs and manufacturing, and 17 were engaged in general and administrative functions, including accounting and finance, administration, and commercial.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?